Engineered neutrophil‐derived vesicles (SOD2‐Fer‐1@CVs) co‐delivering antioxidant and ferroptosis‐inhibitory agents enable inflammation‐targeted, ROS‐responsive therapy for ischemia–reperfusion injury in lung transplantation. Synergizing with ex vivo lung perfusion, this strategy alleviates oxidative stress and inflammation, restores vascular integrity, and improves graft function, offering translational potential for enhancing lung transplant outcomes. Abstract Lung transplantation (LTx) is a life‐saving procedure for patients with end‐stage respiratory failure; however, primary graft dysfunction (PGD), primarily induced by ischemia/reperfusion injury (IRI), remains a major complication. Although ex vivo lung perfusion (EVLP) improves preservation, clinical translation remains challenging owing to IRI complexity. Here, a novel approach is presented to mitigate lung IRI by developing of neutrophil‐derived ROS‐responsive cellular vesicles (SOD2‐Fer‐1@CVs). This hybrid system integrates superoxide dismutase 2 (SOD2)‐overexpressing neutrophil nanovesicles with ROS‐responsive liposomes loaded with ferrostatin‐1 (Fer‐1), a potent ferroptosis inhibitor. SOD2‐Fer‐1@CVs enabled targeted delivery to inflamed tissues and high oxidative stress environments, enabling ROS‐triggered release of SOD2 and Fer‐1. The SOD2‐Fer‐1@CVs system mechanistically targeted the core pathological pathways of IRI, including oxidative stress alleviation, adsorption and neutralization of pro‐inflammatory cytokines, ferroptosis suppression, and restoration of endothelial barrier integrity, with concurrent promotion of macrophage M2 polarization. Using the proprietary small‐animal EVLP platform, the therapeutic administration of SOD2‐Fer‐1@CVs significantly mitigated of reperfusion‐related pathologies and improved graft performance, including enhanced oxygenation, reduced airway resistance, and restored lung compliance, attenuating lung injury after LTx. This study established a novel nanotherapeutic strategy that synergizes with EVLP to address multifactorial IRI, showing high translational potential for improving donor lung quality and LTx outcomes. Engineered neutrophil-derived vesicles (SOD2-Fer-1@CVs) co-delivering antioxidant and ferroptosis-inhibitory agents enable inflammation-targeted, ROS-responsive therapy for ischemia–reperfusion injury in lung transplantation. Synergizing with ex vivo lung perfusion, this strategy alleviates oxidative stress and inflammation, restores vascular integrity, and improves graft function, offering translational potential for enhancing lung transplant outcomes. Abstract Lung transplantation (LTx) is a life-saving procedure for patients with end-stage respiratory failure; however, primary graft dysfunction (PGD), primarily induced by ischemia/reperfusion injury (IRI), remains a major complication. Although ex vivo lung perfusion (EVLP) improves preservation, clinical translation remains challenging owing to IRI complexity. Here, a novel approach is presented to mitigate lung IRI by developing of neutrophil-derived ROS-responsive cellular vesicles (SOD2-Fer-1@CVs). This hybrid system integrates superoxide dismutase 2 (SOD2)-overexpressing neutrophil nanovesicles with ROS-responsive liposomes loaded with ferrostatin-1 (Fer-1), a potent ferroptosis inhibitor. SOD2-Fer-1@CVs enabled targeted delivery to inflamed tissues and high oxidative stress environments, enabling ROS-triggered release of SOD2 and Fer-1. The SOD2-Fer-1@CVs system mechanistically targeted the core pathological pathways of IRI, including oxidative stress alleviation, adsorption and neutralization of pro-inflammatory cytokines, ferroptosis suppression, and restoration of endothelial barrier integrity, with concurrent promotion of macrophage M2 polarization. Using the proprietary small-animal EVLP platform, the therapeutic administration of SOD2-Fer-1@CVs significantly mitigated of reperfusion-related pathologies and improved graft performance, including enhanced oxygenation, reduced airway resistance, and restored lung compliance, attenuating lung injury after LTx. This study established a novel nanotherapeutic strategy that synergizes with EVLP to address multifactorial IRI, showing high translational potential for improving donor lung quality and LTx outcomes. Advanced Science, Volume 12, Issue 42, November 13, 2025.